Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$4.05 USD
+0.12 (3.05%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $4.05 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALDX 4.05 +0.12(3.05%)
Will ALDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALDX
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Other News for ALDX
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Aldeyra Therapeutics Unveils R&D Progress and Goals
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Commit To Purchase Aldeyra Therapeutics At $2.50, Earn 15.5% Annualized Using Options
Fly Insider: Xilio, Aerovate among week���s notable insider trades